Biotech Growth (Ordinary Share) BIOG

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV


Share Price


Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Biotech Growth (Ordinary Share) Price 66.48%
Biotech Growth (Ordinary Share) NAV 68.08%
FTSE World 56.95%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement


Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 727.5 -6.3% 776.00 778.00
26 Apr

Discrete performance % over

Fund / BenchmarkMay '14
Apr '15
May '15
Apr '16
May '16
Apr '17
Biotech Growth (Ordinary Share) Price82.60-20.7415.03
Biotech Growth (Ordinary Share) NAV79.84-20.2817.23
FTSE World21.46-0.2529.54

Discrete performance over

Discrete Performance

Top 10 Holdings

Celgene Corporation 13.27%
Biogen Idec Inc., 11.57%
Incyte Genomics 9.28%
Alexion Pharmaceuticals, Inc. 8.38%
Vertex Pharmaceuticals 7.88%
Amgen Inc 4.99%
Illumina, Inc. 4.09%
DBV Technologies 3.09%
Biomarin Pharmaceuticals, Inc. 2.59%
Regeneron Pharmaceuticals, Inc. 2.59%

Sectors weighting

Biotechnology 98.00%
General Equity 2.30%
Net Current Assets -0.20%

Regional weighting

North America Region 86.00%
Europe Developed ex-UK 10.00%
UK 2.00%
Asia exc Japan 1.00%
Other Countries 1.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 23 Jun 1997
  • Currency GBX
  • Domicile UK
  • Share Price 725.00
  • Share Type Ordinary Share
  • ISIN GB0000385517
  • Shares Issued (M) 56
  • Market Capital (£M) 406.24
  • Gross Assets (£M) 446.68
  • Net Assets (£M) 433.59
  • TER (%) 1.04
  • Last AGM 12 Jul 2016
  • Next AGM 12 Jul 2017
  • Last Annual Report Date 07 Jul 2016
  • Next due Report Date 31 Mar 2017
  • Next due Report Type A/R
  • Objective:

    To achieve capital appreciation through investment in the worldwide biotechnology industry.

  • Management Group(s):

  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • Orbimed Capital LLC
  • Managed by:

  • Geoffrey Hsu Start: 19 May 2005
  • Richard Klemm Start: 19 May 2005
  • Management Contract & Fees:

    Under a new management, administration and company secretarial agreement with Frostrow Capital LLP, Frostrow will receive a periodic fee equal to 0.30% p.a. of the market capitalisation of the Company plus a fixed amount equal to £ 60,000 p.a.. The Investment Manager received a fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may by terminated by either giving notice of not less than 12 months'. A performance fee is calculated quarterly by comparing the cumulative performance of the investment portfolio of the Company with the cumulative performance of the benchmark index since 30-Jun-05. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment manager receiving 15% and Manager 1.5% of the outperformance. At each quarterly calculation date any performance fee payable is based on the lower of: (i) the cumulative outperformance of the investment portfolio over the benchmark index as at the quarter end date; and (ii) the cumulative outperformance of the investment portfolio over the benchmark as at the corresponding quarter end date in the previous year. The Contract can be terminated on 12 months' notice.